Skip to content

Inspection Record

Tripak Pharmaceuticals Pty Ltd. — FDA 483 Findings

US FDAInspected 2025-07-25Published 2026-11-13 5 findingsMaterial and supplier controlStability and storageQuality unit oversightProcess validationLaboratory and QC controls

Inspectors Nibin VargheseThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.

2Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

3Quality unit oversight

The quality control unit lacks the responsibility and authority to approve, reject all drug products.

4Process validation

Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.

5Laboratory and QC controls

Laboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, drug product closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Tripak Pharmaceuticals Pty Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.